

MarÃ-a-Luisa GutiÃ©rrez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2411624/publications.pdf>

Version: 2024-02-01

31
papers

1,349
citations

566801

15
h-index

414034

32
g-index

36
all docs

36
docs citations

36
times ranked

1768
citing authors

#	ARTICLE	IF	CITATIONS
1	MAFLD burden on the Spanish National Health System. A call to action. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	0
2	Plan asistencial coordinado para la eliminaci3n del virus de la hepatitis C en el centro de ayuda integral al drogodependiente (CAID). <i>GastroenterologAa Y HepatologAa</i> , 2021, 44, 214-220.	0.2	0
3	Chronic autoimmune hepatitis triggered by olmesartan. <i>GastroenterologAa Y HepatologAa</i> , 2020, 43, 629-630.	0.2	1
4	Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 264-269.	0.1	16
5	The contribution of telemedicine to hepatitis C elimination in a correctional facility. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 550-555.	0.1	24
6	Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 784-793.	1.1	55
7	Effectiveness, safety/tolerability of OBV/PTV/r A± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice â€“ preliminary data Vie-KinD study. <i>Journal of Hepatology</i> , 2017, 66, S718-S719.	1.8	0
8	Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. <i>PLoS ONE</i> , 2017, 12, e0184550.	1.1	45
9	Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?. <i>BMC Gastroenterology</i> , 2017, 17, 168.	0.8	31
10	Seroprevalencia de hepatitis C en poblaci3n con factores de riesgo del suroeste de la Comunidad de Madrid. <i>GastroenterologAa Y HepatologAa</i> , 2016, 39, 656-662.	0.2	3
11	Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir are Safety and Eficacy for Treating HCV GT1 and 4 Infection in Patients with Severe Renal Impairment or End-Stage Renal Disease: A Multicenter Experience. <i>Journal of Hepatology</i> , 2016, 64, S813.	1.8	4
12	Prevents HBV Reactivation with Tenofovir in Anti-HBc Positive Patients with Hematologic Malignancies Treated with Rituximab. Results Final Visit 18-Months (Preblin Study). <i>Journal of Hepatology</i> , 2016, 64, S369.	1.8	3
13	Non-selective Î²-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000104.	1.1	9
14	Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B. <i>Farmacia Hospitalaria</i> , 2016, 40, 279-86.	0.6	12
15	Labour productivity losses caused by premature death associated with hepatitis C in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 631-637.	0.8	21
16	Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence. <i>World Journal of Gastroenterology</i> , 2015, 21, 8516.	1.4	10
17	Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management. <i>World Journal of Gastroenterology</i> , 2015, 21, 12125.	1.4	51
18	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 46-54.	0.8	4

#	ARTICLE	IF	CITATIONS
19	P1040 TENOFOVIR FOR THE PROPHYLAXIS OF HBV REACTIVATION IN ANTI-HBC-POSITIVE PATIENTS WITH HEMATOLOGIC MALIGNANCIES TREATED WITH RITUXIMAB: PRELIMINARY RESULTS OF A RANDOMIZED STUDY (PREBLIN STUDY). <i>Journal of Hepatology</i> , 2014, 60, S421-S422.	1.8	4
20	Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014, 5, 175.	0.6	25
21	Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 535-542.	0.8	25
22	Acute hepatitis C in Spain: a retrospective study of 131 cases. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 21-28.	0.1	11
23	Pathogenesis of occult chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2011, 17, 1543.	1.4	29
24	Prevalence of occult hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2011, 17, 1538.	1.4	49
25	Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes. <i>World Journal of Gastroenterology</i> , 2011, 17, 1558.	1.4	16
26	Management of occult hepatitis B virus infection: An update for the clinician. <i>World Journal of Gastroenterology</i> , 2011, 17, 1563.	1.4	46
27	548 Sustained response in chronic hepatitis C reduces the risk to develop impaired fasting glucose and/or diabetes mellitus type 2. <i>Journal of Hepatology</i> , 2006, 44, S204.	1.8	4
28	Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 507-512.	1.9	29
29	Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. <i>Gastroenterology</i> , 2005, 128, 636-641.	0.6	699
30	Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. <i>Liver International</i> , 2004, 24, 477-483.	1.9	73
31	Factors Influencing the Rate of Fibrosis Progression in Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1971-1976.	1.1	33